# US 2026/0098095 A1 · Antibodies binding to hla-a2/mage-a4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098095 A1
- Document ID: US20260098095A1
- Status: Published application
- Kind: A1
- Application number: 19/330,067
- Filed: 2025-09-16
- Published: 2026-04-09
- Earliest claimed: 2019-12-18
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Tina WEINZIERL; Lydia Jasmin HANISCH; Alexander BUJOTZEK; Alejandro CARPY GUTIERREZ CIRLOS; Stefan KLOSTERMANN; Christian KLEIN; Simon Patrick KEISER; Tanja FAUTI; Estelle MARRER-BERGER; Pablo UMAÑA
- Web page: https://patentgrep.com/patent/US20260098095A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/35: Valency
- C07K 2317/55: Fab or Fab'
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim 38

A method of treating a cancer in an individual, comprising administering to said individual an effective amount of an antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO: 25, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO: 28, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 29, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 30.

### Claim 39 (depends on 38)

The method of claim 38, wherein the antibody comprises a first antigen binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO: 31, and/or a VL comprising the amino acid sequence of SEQ ID NO: 32.

### Claim 40 (depends on 38)

The method of claim 38, wherein the antibody further comprises a second antigen binding domain which binds to CD3, wherein the second antigen binding domain comprises:
(i) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 59, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 60, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 61, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 62, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 63, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 64; or
(ii) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 51, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 52, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 53, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 54, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 55 and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 56.

### Claim 41 (depends on 40)

The method of claim 40, wherein the antibody further comprises a third antigen binding domain which binds to HLA-A2/MAGE-A4, wherein the third antigen binding domain comprises an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 25, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain variable region (VL) comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 28, an LCDR 2 of SEQ ID NO: 29, and an LCDR 3 of SEQ ID NO: 30.

### Claim 42

A method of treating a cancer in an individual, comprising administering to said individual an effective amount of an antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 1, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 2, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 3, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 4, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 5, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 6.

### Claim 43 (depends on 42)

The method of claim 42, wherein the antibody comprises a first antigen binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO: 7, and/or a VL comprising the amino acid sequence of SEQ ID NO: 8.

### Claim 44 (depends on 42)

The method of claim 42, wherein the antibody further comprises a second antigen binding domain which binds to CD3, wherein the second antigen binding domain comprises:
(i) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 59, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 60, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 61, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 62, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 63, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 64; or
(ii) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 51, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 52, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 53, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 54, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 55 and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 56.

### Claim 45 (depends on 44)

The method of claim 44, wherein the antibody further comprises a third antigen binding domain which binds to HLA-A2/MAGE-A4, wherein the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 1, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 2, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 3, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 4, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 5, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 6.

### Claim 46

A method of treating a cancer in an individual, comprising administering to said individual an effective amount of an antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 41, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 42, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 43, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 44, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 45 and an LCDR 3, comprising the amino acid sequence of SEQ ID NO: 46.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antibody comprises a first antigen binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO: 47, and/or a VL comprising the amino acid sequence of SEQ ID NO: 48.

### Claim 48 (depends on 46)

The method of claim 46, wherein the antibody further comprises a second antigen binding domain which binds to CD3, wherein the second antigen binding domain comprises:
(i) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 59, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 60, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 61, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 62, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 63, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 64; or
(ii) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 51, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 52, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 53, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 54, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 55 and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 56.

### Claim 49 (depends on 48)

The method of claim 48, wherein the antibody further comprises a third antigen binding domain which binds to HLA-A2/MAGE-A4, wherein the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 41, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 42, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 43, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 44, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 45, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 46.

### Claim 50

A method of treating a cancer in an individual, comprising administering to said individual an effective amount of an antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 9, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 10, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 11, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 13, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 14.

### Claim 51 (depends on 50)

The method of claim 50, wherein the antibody comprises a first antigen binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO: 15, and/or a VL comprising the amino acid sequence of SEQ ID NO: 16.

### Claim 52 (depends on 50)

The method of claim 50, wherein the antibody further comprises a second antigen binding domain which binds to CD3, wherein the second antigen binding domain comprises:
(i) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 59, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 60, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 61, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 62, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 63, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 64; or
(ii) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 51, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 52, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 53, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 54, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 55 and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 56.

### Claim 53 (depends on 52)

The method of claim 52, wherein the antibody further comprises a third antigen binding domain which binds to HLA-A2/MAGE-A4, wherein the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 9, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 10, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 11, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 13, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 14.

### Claim 54

A method of treating a cancer in an individual, comprising administering to said individual an effective amount of an antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 17, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 18, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 19, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 20, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 21, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 22.

### Claim 55 (depends on 54)

The method of claim 54, wherein the antibody comprises 54 a first antigen binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO: 23, and/or a VL comprising the amino acid sequence of SEQ ID NO: 24.

### Claim 56 (depends on 54)

The method of claim 54, wherein the antibody further comprises a second antigen binding domain which binds to CD3, wherein the second antigen binding domain comprises:
(i) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 59, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 60, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 61, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 62, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 63, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 64; or
(ii) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 51, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 52, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 53, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 54, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 55 and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 56.

### Claim 57 (depends on 56)

The method of claim 56, wherein the antibody further comprises a third antigen binding domain which binds to HLA-A2/MAGE-A4, wherein the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 17, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 18, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 19, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 20, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 21, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 22.

### Claim 58

A method of treating a cancer in an individual, comprising administering to said individual an effective amount of an antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 33, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 34, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 35, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 36, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 37, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 38.

### Claim 59 (depends on 58)

The method of claim 58, wherein the first antigen binding domain comprises a VH comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 39, and/or a VL comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 40.

### Claim 60 (depends on 58)

The method of claim 58, wherein the antibody further comprises a second antigen binding domain which binds to CD3, wherein the second antigen binding domain comprises:
(i) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 59, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 60, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 61, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 62, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 63, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 64; or
(ii) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 51, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 52, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 53, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 54, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 55 and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 56.

### Claim 61 (depends on 60)

The method of claim 60, wherein the antibody further comprises a third antigen binding domain which binds to HLA-A2/MAGE-A4, wherein the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 33, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 34, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 35, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 36, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 37, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 38.

### Claim 62 (depends on 38)

The method of claim 38, wherein the cancer is a bladder cancer, a brain cancer, a head and neck cancer, a pancreatic cancer, a lung cancer, a breast cancer, an ovarian cancer, a uterine cancer, a cervical cancer, an endometrial cancer, an esophageal cancer, a colon cancer, a colorectal cancer, a rectal cancer, a gastric cancer, a prostate cancer, a blood cancer, a skin cancer, a squamous cell carcinoma, a bone cancer, an ocular cancer, or a kidney cancer.
